DS-5565 Clinical Pharmacology Study An Open-Label, Single-Dose Study to Assess the Pharmacokinetics and Safety of DS-5565 in Japanese Subjects with varying degrees of renal function
Latest Information Update: 07 Dec 2021
At a glance
- Drugs Mirogabalin (Primary)
- Indications Neuropathic pain; Pain; Postherpetic neuralgia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 23 Aug 2017 Results published in the Journal of Clinical Pharmacology
- 30 Sep 2016 Results presented at the 16th World Congress on Pain
- 31 May 2016 New trial record